Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.65 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.65 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887725 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL888110 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL18387242 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL15354501 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL10298024 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL17988585 | 1.00 | MAPK1 (0.71) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL18828676 | 0.92 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19475940 | 0.92 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19614023 | 0.92 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL19605034 | 0.92 | LGALS3 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | MIDATECH LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| EP-2579898-B1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH LTD (GB) | 2019-01-09 | — | — | EP | disclosed |
| EP-2717858-B1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017017063-A2 | NANOPARTICLE-BASED LIVER-TARGETING THERAPY AND IMAGING | MIDATECH LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| EP-2579844-B1 | NANOPARTICLE FILM DELIVERY SYSTEMS | MIDATECH LTD (GB) | 2016-02-24 | — | — | EP | disclosed |
| WO-2012170828-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | MONOSOL RX, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | CALCA, LNPEP, CLTA | MAPK1 3132/4885LGALS8 160/4885LGALS3 99/4885 |
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | LGALS1, CA14, CD44 | MAPK1 764/4885LGALS8 27/4885LGALS3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.